Yanolja Cloud Solution Strengthens Global Presence with New High-Tech Headquarters
Empowering Global Hospitality with a New Vision
As YCS continues to revolutionize hospitality management with comprehensive cloud-based solutions, this move enhances collaboration, innovation, and efficiency, empowering accommodations to optimize operations and boost profitability.
"At Yanolja Cloud Solution, we are redefining hospitality management with comprehensive cloud-based solutions that optimize efficiency, maximize profitability, and deliver superior guest experiences worldwide," said Aeijaz Sodawala, CEO of YCS. "Our new office represents a leap forward in our mission to support the digital transformation of the hospitality industry, and we are thrilled to expand our capabilities in this new space."
Situated in
"As the global hospitality industry continues to transform, Yanolja Cloud Solution's new headquarters in
YCS's cloud-based solutions serve over 33,000 clients across 170+ countries. This relocation strengthens its leadership in hospitality technology and reinforces its commitment to setting new industry standards.
About Yanolja Cloud Solution:
Yanolja Cloud Solution (YCS), one of the few hospitality technology providers worldwide develops and offers end-to-end hotel and restaurant solutions. Acquired by Yanolja Group - the travel tech unicorn of
Photo: https://mma.prnewswire.com/media/2533386/Yanolja_Cloud_Solution_team.jpg
Logo: https://mma.prnewswire.com/media/2533712/Yanolja_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/yanolja-cloud-solution-strengthens-global-presence-with-new-high-tech-headquarters-302279480.html
SOURCE Yanolja Cloud Solution
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
- Solana and Aerodrome Price Prediction: AERO Gains 15% as Remittix Builds Toward Its Exchange Launch
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share